<DOC>
	<DOCNO>NCT02579876</DOCNO>
	<brief_summary>This single-site , double-blind , placebo-controlled , randomized trial study efficacy safety Viaskin® Milk Patch child milk induce Eosinophilic Esophagitis ( EoE ) . 20 subject randomize 3:1 Viaskin® Milk placebo patch .</brief_summary>
	<brief_title>Milk Patch Eosinophilic Esophagitis</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomized trial study efficacy safety Viaskin® Milk , allergen extract milk administer epicutaneously use Viaskin® epicutaneous delivery system ( EPIT ) subject 4 17 year old milk induce Eosinophilic Esophagitis . Subjects randomize 3:1 ratio two different treatment group , receive EPIT Viaskin® Milk ( 500 µg milk protein ) placebo .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Milk Hypersensitivity</mesh_term>
	<criteria>Welldocumented medical history Eosinophilic Esophagitis ingestion milk currently follow strict milkfree diet . Upper endoscopy biopsy initial clinical evaluation Visit 2 show great 15 eosinophils/HPF isolate esophagus meeting consensus diagnosis Eosinophilic Esophagitis , milk reintroduce subject 's diet ( 30 ml/day 1 week 2 month ) , subject proton pump inhibitor . Upper endoscopy biopsy second clinical evaluation Visit 3 show less 5 eosinophil per HPF isolate esophagus minimum 6 week milkfree diet , subject proton pump inhibitor . Negative pregnancy test female subject childbearing potential . Females childbearing potential must use effective method contraception prevent pregnancy agree continue practice acceptable method contraception duration participation study . Sexual abstinence accept effective method contraception girl 18 year age . Subjects and/or parents/guardians willing comply study requirement participation study . Signed informed consent parent ( ) /guardian ( ) child &lt; 18 year + child 's assent . Subjects agree maintain constant diet trial , exception milk . Subjects maintain constant medication asthma allergic rhinitis trial . Subjects history severe anaphylaxis milk follow symptom : hypotension , hypoxia , neurological compromise ( collapse , loss consciousness incontinence ) , Quincke Edema require intubation . Active IgE mediate milk allergy . Pregnancy lactation . Subjects eosinophilic gastrointestinal disorder . Subjects swallow corticosteroid antileukotrienes Eosinophilic Esophagitis . Subjects symptomatic allergy pollen whose symptom correspond pollen season might interfere record symptom upper endoscopy/biopsy , upper endoscopy/biopsy conduct pollen season . The Investigator ensure period conduct upper endoscopy subject outside pollen season . Subjects treat systemic longacting corticosteroid ( depot corticosteroid ) within 12 week prior Visit 1 and/or systemic shortacting corticosteroid within 4 week prior Visit 1 systemic corticosteroid screening . Subjects asthma condition define follow : 1 . Uncontrolled persistent asthma National Asthma Education Prevention Program Asthma guideline ( 2007 ) . 2. least two systemic corticosteroid course asthma past year one oral corticosteroid course asthma past three month ; 3. prior intubation asthma past two year . Subjects βblocking agent , angiotensinconverting enzyme inhibitor , angiotensin receptor blocker , calcium channel blocker tricyclic antidepressant therapy . Subjects undergo type immunotherapy food within one year prior Visit 1 . Subjects presently aeroallergen immunotherapy unwilling unable discontinue . Subjects currently treat antitumor necrosis factor drug antiIgE drug biologic immunomodulatory therapy within one year prior Visit 1 . Allergy known hypersensitivity placebo excipients either Viaskin® Tegaderm® . Subjects suffer generalized dermatologic disease intact skin zone apply Viaskin® , urticarial mast cell disorder chronic idiopathic urticaria . Subjects ( parent subject ) obvious excessive anxiety unlikely cope condition upper endoscopy biopsy . Past current disease ( ) , opinion sponsorinvestigator , may affect subject 's participation study include limit active autoimmune disorder , immunodeficiency , malignancy , uncontrolled disease ( hypertension , psychiatric ( especially anxiety ) , cardiac ) , disorder ( e.g. , liver , gastrointestinal , kidney , cardiovascular , pulmonary disease , blood disorder ) . Any history drug alcohol abuse past five year . Subjects unable follow protocol protocol requirement . Participation another clinical intervention study three month prior Study Visit 1 . Subjects experimental drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Milk Allergy</keyword>
	<keyword>Viaskin Milk</keyword>
	<keyword>Epicutaneous ImmunoTherapy ( EPIT )</keyword>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>Milk-Induced Eosinophilic Esophagitis</keyword>
</DOC>